Medunik Canada has entered into an agreement to market and distribute Orphan Europe Recordati Group's rare diseases access products and services in Canada.
Subscribe to our email newsletter
Under the agreement, Medunik Canada will distribute Orphan’s four therapies for certain medical conditions including acute hepatic porphyria, hyperammonaema due to N-acetylglutamate synthase (NAGS) deficiency or one of three organic acidurias (isovaleric, methylmalonic or propionic), patent ductus arteriosus as well as vitamin E deficiency in chronic cholestasis.
Medunik executive vice-president Eric Gervais said, "This new strategic collaboration complements our existing alliances and represents an important milestone in our endeavor to help patients with a rare disease in Canada to benefit from the best treatments available".
Orphan Europe Recordati Group general manager and special care and orphan drugs vice-president Marco Liguori said, "We are particularly happy to work with a company like Medunik Canada which is committed to building awareness and promoting better diagnosis and care of rare disease patients in Canada."